SEC Filing Summary: GSK Plc (Form 6-K)
Business Context and Reporting Period
This Form 6-K is a transaction notification filed by GlaxoSmithKline plc for the period ending September 26, 2016. The filing reports a specific transaction involving a Person Closely Associated (PCA) with a Principal Director or Manager (PDMR) under the company's 401(K) plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It solely reports a single transaction detail:
- Instrument: GlaxoSmithKline plc American Depositary Shares (ADSs).
- Transaction Type: Increase of 1 ADS via notional allocation.
- Transaction Date: September 22, 2016.
- Price: $43.58 per ADS.
- Volume: 1 ADS.
- Reason: Revaluation of the cash element of the notional investment held within the GSK 401(K) plan.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It is a routine disclosure of an internal employee benefit plan transaction.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. The document is strictly a regulatory notification of a specific share transaction.
Key Facts for Investor Verification
- The filing confirms a minor, automated transaction (1 ADS) within the GSK 401(K) plan for a PCA of Dr. M. M. Slaoui.
- The transaction price of $43.58 reflects the market value on September 22, 2016.
- No financial performance data or strategic updates are provided in this specific document.